Resistance of Leishmania (Viannia) braziliensis to nitric oxide: Correlation with antimony therapy and TNF-α production

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Souza, Anselmo S ^a   Giudice, Angela ^a   Pereira, Júlia M B ^a   Guimarães, Luís H ^a   de Jesus, Amelia R ^b   de Moura, Tatiana R ^b   Wilson, Mary E ^c   Carvalho, Edgar M ^a   Almeida, Roque P ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MEGLUMINE ANTIMONATE; NITRIC OXIDE; SODIUM NITRITE; STIBOGLUCONATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; ANTIMONY; ANTIPROTOZOAL AGENT; TNF PROTEIN, HUMAN;

AMASTIGOTE; ANTHELMINTIC ACTIVITY; ARTICLE; BRAZIL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEISHMANIA BRAZILIENSIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PARASITE ISOLATION; PARASITE VIRULENCE; PHENOTYPIC VARIATION; PROMASTIGOTE; SKIN LEISHMANIASIS; TOXICITY TESTING; CELL CULTURE; DRUG EFFECT; DRUG RESISTANCE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MACROPHAGE; PARASITOLOGY; SECRETION;

ANTIMONY; ANTIPROTOZOAL AGENTS; BRAZIL; CELLS, CULTURED; DRUG RESISTANCE; HUMANS; INTERLEUKIN-10; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; NITRIC OXIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954559533     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-209     Document Type: Article

References (52)

1. Grimaldi G, Tesh RB, McMahon-Pratt D. A review of the geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg 1989, 41:687-725.
2. Carvalho LP, Passos ST, Jesus AR. Imunopatogênese da Leishmaniose Tegumentar. Gaz Med Bahia 2005, 1:57-65.
3. Castes M, Trujillo D, Rojas ME, Fernandez CT, Araya L, Cabrera M, Blackwell J, Convit J. Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. Biol Res 1993, 26:233-238.
4. Carvalho EM, Barral A, Costa JM, Bittencourt A, Marsden P. Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis. Acta Trop 1994, 56:315-325. 10.1016/0001-706X(94)90103-1, 8023755.
5. Costa JM, Marsden PD, Llanos-Cuentas EA, Netto EM, Carvalho EM, Barral A, Rosa AC, Cuba CC, Magalhaes AV, Barreto AC. Disseminated cutaneous leishmaniasis in a field clinic in Bahia Brazil: a report of eight cases. J Trop Med Hyg 1986, 89:319-323.
6. Alexander J, Russell DG. The interaction of Leishmania species with macrophages. Adv Parasitol 1992, 31:175-254. 10.1016/S0065-308X(08)60022-6, 1496927.
7. Alexander J, Satoskar AR, Russell DG. Leishmania species: models of intracellular parasitism. J Cell Sci 1999, 112(18):2993-3002.
8. Liew FY, O'Donnell CA. Immunology of leishmaniasis. Adv Parasitol 1993, 32:161-259. full_text, 8237615.
9. Trinchieri G, Gerosa F. Immunoregulation by interleukin-12. J Leukoc Biol 1996, 59:505-511.
10. Bogdan C, Rollinghoff M, Diefenbach A. The role of nitric oxide in innate immunity. Immunol Rev 2000, 173:17-26. 10.1034/j.1600-065X.2000.917307.x, 10719664.
11. Liew FY, Parkinson C, Millott S, Severn A, Carrier M. Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 1990, 69:570-573. 1385631, 2335376.
12. Liew FY, Wei XQ, Proudfoot L. Cytokines and nitric oxide as effector molecules against parasitic infections. Philos Trans R Soc Lond B Biol Sci 1997, 352:1311-1315. 10.1098/rstb.1997.0115, 1692019, 9355122.
13. Giudice A, Camada I, Leopoldo PT, Pereira JM, Riley LW, Wilson ME, Ho JL, de Jesus AR, Carvalho EM, Almeida RP. Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis. BMC Infect Dis 2007, 7:7. 10.1186/1471-2334-7-7, 1810296, 17316450.
14. Arevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G, Miranda-Verastegui C, Lazo M, Loayza-Muro R, De Doncker S, Maurer A, et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007, 195:1846-1851. 10.1086/518041, 17492601.
15. Berman JD, Edwards N, King M, Grogl M. Biochemistry of Pentostam resistant Leishmania. Am J Trop Med Hyg 1989, 40:159-164.
16. Berman JD, Gallalee JV, Best JM. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem Pharmacol 1987, 36:197-201. 10.1016/0006-2952(87)90689-7, 3028425.
17. Berman JD, Waddell D, Hanson BD. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 1985, 27:916-920. 180186, 2411217.
18. Holzmuller P, Sereno D, Lemesre JL. Lower nitric oxide susceptibility of trivalent antimony-resistant amastigotes of Leishmania infantum. Antimicrob Agents Chemother 2005, 49:4406-4409. 10.1128/AAC.49.10.4406-4409.2005, 1251519, 16189135.
19. Sereno D, Holzmuller P, Mangot I, Cuny G, Ouaissi A, Lemesre JL. Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob Agents Chemother 2001, 45:2064-2069. 10.1128/AAC.45.7.2064-2069.2001, 90601, 11408224.
20. Mookerjee Basu J, Mookerjee A, Sen P, Bhaumik S, Banerjee S, Naskar K, Choudhuri SK, Saha B, Raha S, Roy S. Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother 2006, 50:1788-1797. 10.1128/AAC.50.5.1788-1797.2006, 1472228, 16641451.
21. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006, 19:111-126. 10.1128/CMR.19.1.111-126.2006, 1360270, 16418526.
22. Cupolillo E, Grimaldi G, Momen H. A general classification of New World Leishmania using numerical zymotaxonomy. Am J Trop Med Hyg 1994, 50:296-311.
23. Miller MA, McGowan SE, Gantt KR, Champion M, Novick SL, Andersen KA, Bacchi CJ, Yarlett N, Britigan BE, Wilson ME. Inducible resistance to oxidant stress in the protozoan Leishmania chagasi. J Biol Chem 2000, 275:33883-33889. 10.1074/jbc.M003671200, 10931831.
24. Wilson ME, Andersen KA, Britigan BE. Response of Leishmania chagasi promastigotes to oxidant stress. Infect Immunol 1994, 62:5133-5141.
25. Ettinger NA, Wilson ME. Macrophage and T-Cell Gene Expression in a Model of Early Infection with the Protozoan Leishmania chagasi. PLoS Negl Trop Dis 2008, 2:e252. 10.1371/journal.pntd.0000252, 2427198, 18575603.
26. Assreuy J, Cunha FQ, Epperlein M, Noronha-Dutra A, O'Donnell CA, Liew FY, Moncada S. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol 1994, 24:672-676. 10.1002/eji.1830240328, 8125136.
27. Liew FY, Li Y, Moss D, Parkinson C, Rogers MV, Moncada S. Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur J Immunol 1991, 21:3009-3014. 10.1002/eji.1830211216, 1721024.
28. Brandonisio O, Panaro MA, Fumarola I, Sisto M, Leogrande D, Acquafredda A, Spinelli R, Mitolo V. Macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha induce nitric oxide release and enhance parasite killing in Leishmania infantum-infected human macrophages. Clin Exp Med 2002, 2:125-129. 10.1007/s102380200017, 12447609.
29. Rich EA, Torres M, Sada E, Finegan CK, Hamilton BD, Toossi Z. Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB. Tuber Lung Dis 1997, 78:247-255. 10.1016/S0962-8479(97)90005-8, 10209679.
30. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, Miranda-Verastegui C, Santamaria-Castrellon G, Ramirez L, Lazo M, De Doncker S, Boelaert M, Robays J, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008, 46:223-231. 10.1086/524042, 18171254.
31. Machado P, Araujo C, Da Silva AT, Almeida RP, D'Oliveira A, Bittencourt A, Carvalho EM. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 2002, 34:E69-73. 10.1086/340526, 12032913.
32. Mauel J, Corradin SB, Buchmuller Rouiller Y. Nitrogen and oxygen metabolites and the killing of Leishmania by activated murine macrophages. Res Immunol 1991, 142:577-580. discussion 593-574, 10.1016/0923-2494(91)90106-S, 1812552.
33. Mauel J, Buchmuller-Rouiller Y. Effect of lipopolysaccharide on intracellular killing of Leishmania enriettii and correlation with macrophage oxidative metabolism. Eur J Immunol 1987, 17:203-208. 10.1002/eji.1830170209, 3030768.
34. Channon JY, Roberts MB, Blackwell JM. A study of the differential respiratory burst activity elicited by promastigotes and amastigotes of Leishmania donovani in murine resident peritoneal macrophages. Immunology 1984, 53:345-355. 1454813, 6490087.
35. Murray HW. Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J Immunol 1982, 129:351-357.
36. Zarley JH, Britigan BE, Wilson ME. Hydrogen peroxide-mediated toxicity for Leishmania donovani chagasi promastigotes. Role of hydroxyl radical and protection by heat shock. J Clin Invest 1991, 88:1511-1521. 10.1172/JCI115461, 295659, 1658042.
37. Iyer JP, Kaprakkaden A, Choudhary ML, Shaha C. Crucial role of cytosolic tryparedoxin peroxidase in Leishmania donovani survival drug response and virulence. Mol Microbiol 2008, 68:372-391. 10.1111/j.1365-2958.2008.06154.x, 18312262.
38. Lemesre JL, Sereno D, Daulouede S, Veyret B, Brajon N, Vincendeau P. Leishmania spp.: nitric oxide-mediated metabolic inhibition of promastigote and axenically grown amastigote forms. Exp Parasitol 1997, 86:58-68. 10.1006/expr.1997.4151, 9149241.
39. Iniesta V, Gomez-Nieto LC, Molano I, Mohedano A, Carcelen J, Miron C, Alonso C, Corraliza I. Arginase I induction in macrophages triggered by Th2-type cytokines supports the growth of intracellular Leishmania parasites. Parasite Immunol 2002, 24:113-118. 10.1046/j.1365-3024.2002.00444.x, 11982856.
40. Roberts SC, Tancer MJ, Polinsky MR, Gibson KM, Heby O, Ullman B. Arginase plays a pivotal role in polyamine precursor metabolism in Leishmania. Characterization of gene deletion mutants. J Biol Chem 2004, 279:23668-23678. 10.1074/jbc.M402042200, 15023992.
41. Genestra M, Souza WJ, Guedes-Silva D, Machado GM, Cysne-Finkelstein L, Bezerra RJ, Monteiro F, Leon LL. Nitric oxide biosynthesis by Leishmania amazonensis promastigotes containing a high percentage of metacyclic forms. Arch Microbiol 2006, 185:348-354. 10.1007/s00203-006-0105-9, 16575586.
42. Gaur U, Showalter M, Hickerson S, Dalvi R, Turco SJ, Wilson ME, Beverley SM. Leishmania donovani lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts. Exp Parasitol 2009, 122:182-191. 10.1016/j.exppara.2009.03.014, 2720449, 19328787.
43. Carrera L, Gazzinelli RT, Badolato R, Hieny S, Muller W, Kuhn R, Sacks DL. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 1996, 183:515-526. 10.1084/jem.183.2.515, 2192469, 8627163.
44. Bacellar O, Lessa H, Schriefer A, Machado P, de Jesus Ribeiro A, Dutra WO, Gollob KJ, Carvalho EM. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002, 70:6734-6740. 10.1128/IAI.70.12.6734-6740.2002, 132996, 12438348.
45. Olivier M, Gregory DJ, Forget G. Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev 2005, 18:293-305. 10.1128/CMR.18.2.293-305.2005, 1082797, 15831826.
46. Padigel UM, Alexander J, Farrell JP. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J Immunol 2003, 171:3705-3710.
47. Belley A, Chadee K. Eicosanoid production by parasites: from pathogenesis to immunomodulation?. Parasitol Today 1995, 11:327-334. 10.1016/0169-4758(95)80185-5, 15275314.
48. Bogdan C, Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 1998, 28:121-134. 10.1016/S0020-7519(97)00169-0, 9504340.
49. Gantt KR, Schultz-Cherry S, Rodriguez N, Jeronimo SM, Nascimento ET, Goldman TL, Recker TJ, Miller MA, Wilson ME. Activation of TGF-beta by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol 2003, 170:2613-2620.
50. Green SJ, Scheller LF, Marletta MA, Seguin MC, Klotz FW, Slayter M, Nelson BJ, Nacy CA. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunol Lett 1994, 43:87-94. 10.1016/0165-2478(94)00158-8, 7537721.
51. Nelson BJ, Ralph P, Green SJ, Nacy CA. Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1. J Immunol 1991, 146:1849-1857.
52. Stenger S, Thuring H, Rollinghoff M, Bogdan C. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J Exp Med 1994, 180:783-793. 10.1084/jem.180.3.783, 2191630, 7520472.